Aims Salivary duct carcinoma (SDC) is an aggressive salivary malignancy that results in
high mortality rates and is often resistant to chemotherapy. Anti‐programmed death‐1 (PD …

Background and Objectives The immune checkpoint ligand programmed death ligand‐1
(PD‐L1) is expressed in various carcinomas and allows carcinoma cells to elude the …

Background Salivary duct carcinoma (SDC) is a rare tumor occurring in the salivary gland.
SDC is a highly aggressive tumor and its prognosis is extremely poor. Effective treatments in …

Objectives PD-1/PD-L1 and CTLA-4 have been investigated and are thought to play an
important role in tumor evasion. This study aimed to investigate expression patterns of …

Background: Malignant neoplasms of the salivary glands are rare, and therapeutic options
are limited. Results from recently published studies indicate a possible use for checkpoint …

Background To investigate the differential expression of PD-1 and PD-L1 in salivary gland
tumors (SGTs, malignant and benign subtypes) and determine their association with the …

Objective PD-L1 is one of the predictors of immunotherapy efficacy. Our goal was to analyze
its expression and prognostic significance in high-grade salivary gland carcinoma (SGC) …

Abstract Background Programmed death-1 ligand-1 (PD-L1) an important cancer biomarker
that can suppress the immune system and its high expression is often reported to be related …

Objectives The aim of the present study was to investigate the molecular basis for the use of
immune checkpoint inhibitors to treat salivary gland carcinomas (SGC). Materials and …

Background Immune checkpoint inhibitors play an increasing role in oncologic care. PD-L1
expression is associated with survival and predicts response to PD-1 or PD-L1 inhibitors in a …